<DOC>
	<DOCNO>NCT01350778</DOCNO>
	<brief_summary>The objective study evaluate effectiveness safety BioMatrix stent `` real world '' daily practice compare first-generation drug-eluting stent ( sirolimus- paclitaxel-eluting stent ) .</brief_summary>
	<brief_title>Evaluation Effectiveness Safety BIOMATRIX Stent ( IRIS-BIOMATRIX )</brief_title>
	<detailed_description>This study non-randomized , prospective , open-label registry compare efficacy safety BioMatrix stent versus first-generation drug-eluting stent ( DES ) patient coronary artery disease .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients receive BioMatrix stents The patient guardian agree study protocol schedule clinical followup , provide informed , write consent , approve appropriate Institutional Review Board/Ethics Committee respective clinical site . Patients mixture DESs Terminal illness life expectancy &lt; 1 year Patients cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Coronary artery disease require drug elute stent</keyword>
</DOC>